Elizabeth Christie lab

The Christie lab, also known as the Elizabeth Christie lab, seeks to understand how ovarian and endometrial cancers evolve to become resistant to treatment, develop biomarkers of treatment response and identify treatments that can overcome resistance

Acquired treatment resistance, whereby patients respond well to primary treatment but eventually develop drug resistance, is common across a range of cancer types. It is particularly problematic in the most common form of ovarian cancer, high-grade serous ovarian cancer, and high-risk endometrial cancer. The Elizabeth Christie lab seeks to: 

  • identify the mechanisms of acquired treatment resistance that arise in high-grade serous ovarian cancer and high-risk endometrial cancer 
  • identify treatments that can overcome resistance 
  • develop tumour-based and circulating tumour DNA biomarkers of resistance 
  • understand the metastatic processes that occur in high-grade serous ovarian cancer.

Current projects

Related links

Elizabeth Christie Twitter

Related pages